Hepion Pharmaceuticals (HEPA) Competitors $0.05 0.00 (-4.52%) As of 02:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HEPA vs. PCSA, ENVB, LIPO, PRFX, RDHL, PWUP, ELAB, ADTX, CANF, and PTNShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Heatwurx (PCSA), Enveric Biosciences (ENVB), Lipella Pharmaceuticals (LIPO), PainReform (PRFX), Redhill Biopharma (RDHL), PowerUp Acquisition (PWUP), PMGC (ELAB), Aditxt (ADTX), Can-Fite BioPharma (CANF), and Palatin Technologies (PTN). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Its Competitors Heatwurx Enveric Biosciences Lipella Pharmaceuticals PainReform Redhill Biopharma PowerUp Acquisition PMGC Aditxt Can-Fite BioPharma Palatin Technologies Heatwurx (NASDAQ:PCSA) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Does the media favor PCSA or HEPA? In the previous week, Heatwurx's average media sentiment score of 0.67 beat Hepion Pharmaceuticals' score of 0.00 indicating that Heatwurx is being referred to more favorably in the media. Company Overall Sentiment Heatwurx Positive Hepion Pharmaceuticals Neutral Which has better valuation & earnings, PCSA or HEPA? Heatwurx is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.09Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Do institutionals and insiders have more ownership in PCSA or HEPA? 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is PCSA or HEPA more profitable? Heatwurx's return on equity of -342.36% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% Hepion Pharmaceuticals N/A -812.56%-207.31% Which has more risk & volatility, PCSA or HEPA? Heatwurx has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Do analysts prefer PCSA or HEPA? Heatwurx currently has a consensus price target of $2.00, indicating a potential upside of 817.43%. Given Heatwurx's stronger consensus rating and higher probable upside, research analysts plainly believe Heatwurx is more favorable than Hepion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryHeatwurx beats Hepion Pharmaceuticals on 9 of the 12 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$628K$832.54M$5.76B$9.59BDividend YieldN/A4.84%4.41%4.09%P/E Ratio-0.011.1522.4021.92Price / SalesN/A26.21472.14121.31Price / CashN/A19.5637.7358.48Price / Book0.046.659.536.61Net Income-$48.93M-$4.94M$3.26B$265.56M7 Day PerformanceN/A0.95%2.11%1.98%1 Month PerformanceN/A2.99%5.12%1.33%1 Year PerformanceN/A11.85%31.25%21.15% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.9612 of 5 stars$0.05-4.5%N/A-99.9%$628KN/A-0.0120PCSAHeatwurx2.9993 of 5 stars$0.22-3.9%$2.00+796.9%-86.5%$2.76MN/A-0.1020ENVBEnveric Biosciences2.3266 of 5 stars$1.09-1.8%$10.00+817.4%-85.9%$2.74MN/A-0.0320LIPOLipella PharmaceuticalsN/A$0.60+6.2%N/A-83.1%$2.68M$536.36K-0.154PRFXPainReform1.5553 of 5 stars$1.38+3.8%N/A+48.2%$2.68MN/A-0.014Gap UpRDHLRedhill BiopharmaN/A$1.27+9.5%N/A-88.1%$2.66M$8.04M0.00210Gap DownPWUPPowerUp AcquisitionN/A$0.34+0.8%N/AN/A$2.61MN/A0.00N/AHigh Trading VolumeELABPMGC0.9289 of 5 stars$1.93+2.7%N/A-99.4%$2.59M$1.71M0.0018News CoverageADTXAditxt0.3733 of 5 stars$1.13-5.0%N/A-100.0%$2.52M$130K0.0060News CoverageGap UpCANFCan-Fite BioPharma2.0272 of 5 stars$0.70+1.4%$14.00+1,908.6%-70.7%$2.47M$674K-0.398Negative NewsPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading Volume Related Companies and Tools Related Companies PCSA Alternatives ENVB Alternatives LIPO Alternatives PRFX Alternatives RDHL Alternatives PWUP Alternatives ELAB Alternatives ADTX Alternatives CANF Alternatives PTN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HEPA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access